Navigation Links
Drugs to treat cocaine abuse?
Date:8/10/2010

Philadelphia, PA, 10 August 2010 - The authors of a new study in Biological Psychiatry explore pharmacological strategies for reducing cocaine self-administration in animals that may have implications for treating cocaine dependence in humans.

Glutamate is the primary excitatory neurotransmitter in the brain, which has been implicated in drug addiction. Metabotropic glutamate receptors (mGluRs) represent a family of G-protein coupled receptors that modulate glutamate transmission. Glutamate is an important neurotransmitter involved in learning and memory. Today, these receptors are considered to be promising targets for drug discovery, with therapeutic potential to treat various neurological and psychiatric disorders, including drug addiction.

Scientists from The Scripps Research Institute examined whether dysregulation of mGluRs function is a factor in escalating cocaine self-administration in rats. Rats with a history of daily short (1 hour) or long (6 hours) access to cocaine were tested for differences in cocaine consumption after receiving treatment with LY379268, an mGluR2/3 agonist, and MTEP, an mGluR5 antagonist.

They found that the capacity of LY379268 and MTEP to diminish cocaine use changed into opposite directions during development to addiction. LY379268 became more effective, whereas MTEP lost its effect in cocaine dependent rats (long-access). These behavioral changes were paired with distinct changes in the function of mGlu2/3 and mGlu5 receptors.

Dr. Yue Hao, corresponding author of this study, explains their findings: "We provide novel evidence that during the transition from 'casual' cocaine use to addiction, dysregulation develops in both mGlu2/3 and mGlu5 function as reflected by enhanced mGlu2/3 activity and decreased mGlu5 expression." These data suggest that changes in the function of mGlu2 and mGlu5 receptors may play a role in the transition to cocaine addiction.

According to the authors, these new findings identify mGlu2/3 receptors as a particularly promising treatment target for severely cocaine-addicted individuals.

In contrast, the treatment target potential of mGlu5 receptors may be limited to early stages of cocaine abuse.

"This type of study highlights an aspect of the complexity that may be associated with the pharmacotherapy of treating cocaine dependence. All types of cocaine use may not be alike," comments Dr. John Krystal, Editor of Biological Psychiatry. "Cocaine exposure to different extents may produce different adaptations in the brain systems. The different profile of the effects of mGluR2/3 agonists and mGluR5 antagonists is interesting and it should stimulate further research."


'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Epilepsy Drugs Dont Raise Suicide Risk, Study Shows
2. Recession Causing Cancer Patients to Quit Life-Extending Drugs
3. New Data Supports Link Between Diabetes Drugs, Fractures
4. Popular diabetes drugs associated with fractures in type 2 diabetic patients
5. Not All Epilepsy Drugs Raise Suicide Risk: Study
6. Non-human sugar in biotech drugs causes inflammation
7. Most men in long-term study of HIV report low use of illicit drugs
8. Experts Issue New Guidelines on Breast Cancer Drugs
9. Drugs Like Viagra Linked to Higher Rates of STDs
10. Teen Girls Becoming More Open to Drugs, Alcohol
11. Breast milk transmits drugs and medicines to the baby
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... The ... Recovery, the leading national organization representing the growing community of recovering individuals (now ... to include Family Recovery in policies addressing addiction. , Although many of ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... DC (PRWEB) , ... February ... ... Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop ... The partnership will recruit top students from U.S. universities who will draw ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for certain ... Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... Feb. 12, 2016  Memorial Hermann Health System has ... Howard to bring a one-of-a-kind experience to pediatric ... cutting-edge technologies such as 360-degree video and Google Cardboard, ... then literally – giving the patients and their families ... was all caught on video . ...
(Date:2/12/2016)... , Feb. 12, 2016 On Thursday, Feb. ... Surgery at St. David,s North Austin Medical Center successfully ... ® Xi ® Surgical System with Trumpf ... Thiru Lakshman , M.D., colorectal surgeon at ... proctocolectomy utilizing Integrated Table Motion technology, which seamlessly combines ...
Breaking Medicine Technology: